MRK

Merck & Co., Inc. · Healthcare · Drug Manufacturers - General
$118.72
-1.17 (-0.98%)
Mkt Cap: 293.22B
Key Metrics
MetricValue
P/E RatioN/A
EV/EBITDAN/A
ROEN/A
Gross MarginN/A
Revenue GrowthN/A
FCF Yield4.7%
Dividend YieldN/A
Market Cap293.22B
Volume6.34M
Recent News
Can MRK's New Drugs & Pipeline Aid Long-Term Growth Post Keytruda LOE?
zacks.com · 2026-05-29
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung
gurufocus.com · 2026-05-29
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
businesswire.com · 2026-05-29
VYM vs. SCHD: Which U.S. Dividend ETF Is a Better Buy?
fool.com · 2026-05-29
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
zacks.com · 2026-05-28
Merck to Participate in the Jefferies Global Healthcare Conference
businesswire.com · 2026-05-28

Unlock the Full Deep Scan

9 AI agents analyze MRK across earnings, insider flow, macro conditions, corporate strategy, market microstructure, and price action.

Sign Up Free →